Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: The company manufactures medical devices, including stand-alone products (e.g., inflation devices, Fountain Infusion Catheters) and custom kits. Operations include domestic facilities and a subsidiary in Ireland.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Sales | $17,701,723 | $16,466,015 |
| Gross Profit | $6,692,102 | $6,163,161 |
| Gross Margin | 37.8% | 37.4% |
| Operating Income | $1,070,736 | $1,108,003 |
| Net Income | $565,123 | $427,655 |
| Earnings Per Share (Diluted) | $0.08 | $0.06 |
| Cash from Operations | $772,385 | ($87,967) |
| Working Capital | $15,502,979 | N/A |
| Line of Credit Outstanding | $8,253,246 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 8% ($1.24 million) driven by a 16% increase in stand-alone products (specifically inflation devices up 17%) and a 2% increase in custom kits.
- Profitability: Net income rose 32% despite a 3.4% decline in operating income. This divergence was primarily due to a reduced effective tax rate (30% vs. 50% in Q1 1998) resulting from the Irish subsidiary turning profitable.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased as a percentage of sales (27.2% vs. 25.3%) due to costs associated with implementing an Oracle integrated business system and Year 2000 (Y2K) compliance. R&D expenses decreased by $86,490.
- Cash Flow: Operating cash flow improved significantly from a negative $88,000 in Q1 1998 to a positive $772,000 in Q1 1999. However, investing activities consumed $973,000 due to capital expenditures.
Outlook, Risks, and Management Commentary
- Liquidity: The company maintains a current ratio of 1.9 to 1 with a $10.5 million secured bank line of credit. Management believes current liquidity is adequate for operations.
- Year 2000 (Y2K) Compliance: Approximately $3.5 million has been incurred to date for IT system upgrades and Y2K readiness, with an additional $500,000 anticipated. The company expects completion by September 30, 1999. Risks include potential disruptions from third-party suppliers or customers failing to achieve Y2K compliance.
- Market Risks: The company faces risks related to foreign currency fluctuations and variable interest rates on debt but currently does not hedge these exposures. Other risks include product recalls, regulatory approval delays, and healthcare reform initiatives.
- Guidance: No specific numerical guidance for future quarters was provided in this filing.
Investor Verification Checklist
- Verify the sustainability of the improved effective tax rate given the volatility of the Irish subsidiary's profitability.
- Monitor the actual costs and timeline for the remaining $500,000 in Y2K compliance expenditures.
- Assess the impact of increased SG&A expenses related to the Oracle system implementation on future margins.
- Review the utilization of the $10.5 million line of credit, currently at $8.25 million, to ensure adequate borrowing capacity remains.
- Confirm the status of major suppliers' Y2K compliance to mitigate supply chain disruption risks.